A Prospective, Randomized, Placebo-Controlled Study of a Combination of Simvastatin and Chemotherapy in Metastatic Breast Cancer

Table 5

Differences in TC, LDL-C, and HDL-C levels during each chemotherapy cycle.

Variable	Simvastatin		Placebo
	Differences between 1^st and 8^th day of each chemotherapy cycle
	Mean (%)	value	Mean (%)	value
TC (mg/dl)
Cycle 1	−15.67 (−9.54%)	0.007	−18.13 (−8.57%)	0.003
Cycle 2	−15.91 (−9.07%)	0.013	−20.47 (−9.43%)	0.0002
Cycle 3	−13.58 (−7.81%)	0.018	−13.52 (−6.6%)	0.017
Cycle 4	−16.05 (−9.01%)	0.013	−19.45 (−8.71%)	0.002
Cycle 5	−14.29 (−8.43%)	0.016	−20.13 (−9.16%)	0.001
Cycle 6	−8.17 (−4.85%)	0.3	−7 (−3.26%)	0.3
LDL-C (mg/dl)
Cycle 1	−10.42 (−11.75%)	0.006	−16 (−12.73%)	0.001
Cycle 2	−16.85 (−16.77%)	0.0006	−8.71 (−6.7%)	0.014
Cycle 3	−10.02 (−9.84%)	0.018	−9.84 (−7.85%)	0.006
Cycle 4	−11.41 (−10.94%)	0.008	−15.59 (−11.4%)	0.0002
Cycle 5	−6.29 (−6.44%)	0.2	−7.31 (−5.53%)	0.056
Cycle 6	−7.17 (−7.31%)	0.29	−3.85 (−2.82%)	0.6
HDL-C (mg/dl)
Cycle 1	0.52 (1.06%)	0.5	−3.47 (−6.77%)	0.1
Cycle 2	0.06 (0.12%)	0.9	−4.65 (−8.58%)	0.06
Cycle 3	0.03 (0.07%)	0.9	−0.55 (−1.12%)	0.8
Cycle 4	0.22 (0.46%)	0.9	0.23 (0.45%)	0.9
Cycle 5	−0.21 (−0.45%)	0.9	−5.31 (−9.38%)	0.03
Cycle 6	0.23 (0.48%)	0.9	−0.46 (−0.84%)	0.8